Compugen (CGEN) News
NASDAQ: CGENHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
1.84-0.04 (-2.13%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CGEN news summary
We found 3 recent headlines mentioning Compugen (CGEN): 0 in the past week and 3 in the past 30 days, most often from Nasdaq. For price context, CGEN is down 2.13% at $1.84. The most recent story, "Compugen (CGEN) Q3 2026 Earnings Call Transcript", was published by Nasdaq on Nov 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Compugen headlines
- Compugen (CGEN) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- Compugen Ltd. Reports Third Quarter 2026 ResultsCompugen Ltd. reported its financial results for the third quarter of 2026 and provided a corporate update. As of September 30, 2026, the company had approximately $117.5 million in cash, cash…Nasdaq
- BioMarin Pharmaceutical (BMRN) Q3 Earnings Surpass EstimatesBioMarin (BMRN) delivered earnings and revenue surprises of +355.56% and -0.23%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?NasdaqBMRN, CGEN